<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2078">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04442087</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200627</org_study_id>
    <secondary_id>2020-A01480-39</secondary_id>
    <nct_id>NCT04442087</nct_id>
  </id_info>
  <brief_title>Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP</brief_title>
  <acronym>FamilyPEDCOVID</acronym>
  <official_title>Seroprevalence of Anti-SARS-CoV2 Among Children According to Parents' SARS-CoV2 Serological Status. Study in a Hospital Population Assistance Publique-Hôpitaux Paris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to define seroprevalence of anti-SARS-CoV2 among children of
      Hospital Workers in APHP, particularly exposed population, according to parents' SARS-CoV2
      serological status.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprevalence of antibodies anti- SARS Cov2 in children of Hospital workers</measure>
    <time_frame>at inclusion</time_frame>
    <description>Percentage of children with seropositive according to parents' SARS Cov2 serological status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Asymptomatic Children with a positive seroloy</measure>
    <time_frame>At inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of severely symptomatic Children with a positive serology</measure>
    <time_frame>At inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of different clinical symptoms in children with a positive serology</measure>
    <time_frame>At inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serological result of each member of the family</measure>
    <time_frame>At inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of spouses of hospital workers with a positive serology</measure>
    <time_frame>At inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Asymptomatic spouses of hospital workers with a positive serology</measure>
    <time_frame>At inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of severely symptomatic spouses of hospital workers with a positive serology</measure>
    <time_frame>At inclusion</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>SARS-CoV2</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Serology SARS-CoV2</intervention_name>
    <description>Collect serum for Serology SARS-CoV2 at inclusion</description>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Collect clinical and demographic data, habitus, Lifestyle Counseling at inclusion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Hospital workers :

          1. Individuals aged over 18, having a professional activity at the APHP (employees,
             interns, volunteers)

          2. Affiliated to a social security regimen

          3. Have at least one child under the age of 18 living in the same house.

          4. have signed consent

        Child (ren), spouse and other member (s) residing at household:

        Child (ren), spouse and any other member residing in the household of a professional of the
        Paris Center Hospitals meeting the inclusion criteria above.

        Exclusion Criteria:

        Refuse to participate in research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Solen KERNEIS, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flore ROZENBERG, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Marc TRELUYER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Marc Treluyer, MD, PhD</last_name>
    <phone>01 44 49 43 28</phone>
    <email>jean-marc.treluyer@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie JOLAINE, Master</last_name>
    <phone>+33 1 42 19 28 79</phone>
    <email>valerie.jolaine@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre d'investigation clinique (CIC) Necker Cochin in Necker Children's Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela SEMERARO, MD</last_name>
      <email>michaela.semeraro@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Michaela SEMERARO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Serology</keyword>
  <keyword>Hospital workers</keyword>
  <keyword>Children</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

